Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03802981
Other study ID # 18-541
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 9, 2019
Est. completion date January 2026

Study information

Verified date May 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 338
Est. completion date January 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Age greater than 18 years - Have two or more GGOs on initial CT imaging - GGOs must be measure =3.0 cm and =0.6 cm in the greatest dimension - GGOs must be greater than half ground glass A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria. Exclusion Criteria: - Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment. - The presence of any solid lesion =0.6 cm suspicious for malignancy. - Patients who are actively undergoing treatment for other malignancies

Study Design


Related Conditions & MeSH terms

  • Multiple Ground Glass Opacities (GGOs)

Locations

Country Name City State
Canada McMaster University (Data Collection Only) Hamilton Ontario
Canada Centre Hospitalier de l'Université de Montreal Montréal Quebec
Canada University Health Network Toronto Ontario
United States Lehigh Valley Health Network Allentown Pennsylvania
United States University of Michigan Ann Arbor Michigan
United States Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey
United States Brigham and Women's Hospital Boston Massachusetts
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States Roswell Park Cancer Institute (Data Collection Only) Buffalo New York
United States Rush University Medical Center (Data collection only) Chicago Illinois
United States Memorial Sloan Kettering Commack Commack New York
United States Duke University Medical Center Durham North Carolina
United States Memorial Sloan Kettering Westchester Harrison New York
United States Hartford Healthcare Hartford Connecticut
United States Baylor University Medical Center Houston Texas
United States MD Anderson Cancer Center Houston Texas
United States Memorial Sloan Kettering Monmouth Middletown New Jersey
United States Memorial Sloan Kettering Bergen Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York
United States New York Presbyterian Hospital New York New York
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Temple University Philadelphia Pennsylvania
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania
United States University of Pennsylvania (Data Collection Only) Philadelphia Pennsylvania
United States Allegheny Health Network Pittsburgh Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States George Washington University School of Medicine Saint Louis Missouri
United States Washington University School of Medicine Saint Louis Missouri
United States University of California San Diego San Diego California
United States Stanford University Medical Center (Data collection only) Stanford California
United States Memorial Sloan Kettering Nassau Uniondale New York

Sponsors (9)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Brigham and Women's Hospital, Duke University, M.D. Anderson Cancer Center, Mayo Clinic, Université de Montréal, University of Pittsburgh, University of Toronto, Washington University School of Medicine

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary lung cancer-specific survival 5 years